You are here

Zealand Pharma

Boehringer moves obesity therapy into phase 3

Boehringer moves obesity therapy into phase 3

Pharmaphorum

Boehringer Ingelheim

clinical trials

Flag link:

Spotlight – Nash in 2023 and beyond

Spotlight – Nash in 2023 and beyond

EP Vantage

Boehringer Ingelheim

Akero Therapeutics

Ionis Pharmaceuticals

Gilead Sciences

Ascletis Pharma

Flag link:

Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect

Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect

Fierce Biotech

Boehringer Ingelheim

clinical trials

Flag link:

Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial

Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial

BioSpace

Boehringer Ingelheim

clinical trials

Flag link:

Boehringer signals intent in obesity

Boehringer signals intent in obesity

EP Vantage

Boehringer Ingelheim

clinical trials

Flag link:

Zealand Pharma reports data from Phase III short bowel syndrome trial

Zealand Pharma reports data from Phase III short bowel syndrome trial

Clinical Trials Arena

clinical trials

short bowel syndrome

Flag link:

Zealand Pharma, Novo Nordisk Ink Licensing Pact For Diabetes Drug

Zealand Pharma, Novo Nordisk Ink Licensing Pact For Diabetes Drug

Yahoo/Benzinga

Flag link:

Key data catalysts for the industry’s small players

Key data catalysts for the industry’s small players

EP Vantage

Intercept Pharma

atopic dermatitis

short bowel syndrome

Assembly Biosciences

Flag link:

MannKind Acquires Wearable Insulin Device from Zealand Pharma

MannKind Acquires Wearable Insulin Device from Zealand Pharma

Medical Devices and Diagnostics Industry

Flag link:

Workforce Cuts Abound at Zealand Pharma, Merck and Orchard

Workforce Cuts Abound at Zealand Pharma, Merck and Orchard

BioSpace

Orchard Therapeutics

Flag link:

After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia

After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia

Endpoints

Flag link:

Zealand acquires a struggling diabetes med-tech in push into US market

Zealand acquires a struggling diabetes med-tech in push into US market

Endpoints

Flag link:

Zealand’s Severe Hypoglycemia Treatment Hits the Mark in Another Phase III Trial

Zealand’s Severe Hypoglycemia Treatment Hits the Mark in Another Phase III Trial

BioSpace

Flag link:

Alexion adds to pipeline with two early-stage R&D deals

Alexion adds to pipeline with two early-stage R&D deals

BioPharma Dive

Alexion Pharmaceuticals

Flag link:

Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII

Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII

Endpoints

short bowel syndrome

Flag link:

Sanofi's LixiLan Progresses

Sanofi's LixiLan Progresses

Yahoo/Zacks.com

Flag link:

Zealand Pharma, Eli Lilly sign obesity, diabetes research deal

Zealand Pharma, Eli Lilly sign obesity, diabetes research deal

Reuters

Flag link:

Zealand Pharma Announces GetGoal Duo 1 and GetGoal-L Phase III Data on Lixisenatide (Lyxumia(R))1 to be Presented at ADA

Zealand Pharma Announces GetGoal Duo 1 and GetGoal-L Phase III Data on Lixisenatide (Lyxumia(R))1 to be Presented at ADA

Yahoo/Global NewsWire

type 2 diabetes

Flag link: